Deepti Vats
Psychiatry · Terrell, TXNPI 1932496262
Payments from drug & device makers
Across 105 payments — averaging $26.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$645
- Axsome Therapeutics, Inc.$329
- AbbVie$303
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$259
- Takeda Pharmaceuticals U.S.A., Inc.$258
- Tris Pharma Inc$236
- plus $756 from 12 others
What the payments were for
- Food & beverage$2,785100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 29 | $645 |
| Axsome Therapeutics, Inc. | 7 | $329 |
| AbbVie | 15 | $303 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $259 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $258 |
| Tris Pharma Inc | 5 | $236 |
| Lundbeck LLC | 8 | $161 |
| Teva Pharmaceuticals USA, Inc. | 1 | $129 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Supernus Pharmaceuticals, Inc. | 3 | $96 |
| Tempus AI, Inc | 1 | $96 |
| Almatica Pharma LLC | 2 | $36 |
| Noven Therapeutics, LLC | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Brainsway USA Inc | 1 | $18 |
| Noven Pharmaceuticals, Inc. | 1 | $15 |
| Alkermes, Inc. | 1 | $14 |
| Orexo US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dyanavel XR$172
- UZEDY$129
- Auvelity$124
- COBENFY$122
- CAPLYTA$106
How this compares
$2,785 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 14 | $9,926 |
| LyricaPregabalin | 11 | $5,473 |
| Aripiprazole | 30 | $2,065 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 15 | $1,842 |
| Bupropion XlBupropion Hcl | 63 | $1,283 |
| Duloxetine Hcl | 56 | $977 |
| Trazodone Hcl | 61 | $706 |
| Quetiapine Fumarate | 21 | $586 |
| Fluoxetine Hcl | 24 | $486 |
| Lamotrigine | 24 | $402 |
| Propranolol Hcl | 25 | $393 |
| Bupropion Hcl SrBupropion Hcl | 13 | $238 |
| Clonazepam | 69 | $234 |
| Alprazolam | 43 | $209 |
| Buprenorphine Hcl | 12 | $185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $258 | $9,92614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Terrell
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
- Sejal MehtaPlano$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.